• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与腹泻型肠易激综合征相关的肠道微生物失调可以在黏膜人工结肠(M-ARCOL)中得到有效模拟。

Gut microbial dysbiosis associated to diarrheic irritable bowel syndrome can be efficiently simulated in the Mucosal ARtificial COLon (M-ARCOL).

作者信息

Uriot Ophélie, Deschamps Charlotte, Scanzi Julien, Brun Morgane, Kerckhove Nicolas, Dualé Christian, Fournier Elora, Durif Claude, Denis Sylvain, Dapoigny Michel, Langella Philippe, Alric Monique, Etienne-Mesmin Lucie, Stéphanie Blanquet-Diot

机构信息

UMR 454 MEDIS, Microbiologie Environnement Digestif et Santé, Université Clermont Auvergne - INRAE, Clermont-Ferrand, Puy-de-Dôme,France.

UMR INSERM 1107 NEURO-DOL, Université Clermont Auvergne, Clermont-Ferrand, Puy-de-Dôme,France.

出版信息

Bioengineered. 2025 Dec;16(1):2458362. doi: 10.1080/21655979.2025.2458362. Epub 2025 Feb 4.

DOI:10.1080/21655979.2025.2458362
PMID:39902883
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11796540/
Abstract

Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder, with diarrhea-predominant IBS (IBS-D) as the most frequent subtype. The implication of gut microbiota in the disease's etiology is not fully understood. gut systems can offer a great alternative to assays in preclinical studies, but no model reproducing IBS-related dysbiotic microbiota has been developed. Thanks to a large literature review, a new Mucosal ARtifical COLon (M-ARCOL) adapted to IBS-D physicochemical and nutritional conditions was set-up. To validate the model and further exploit its potential in a mechanistic study, fermentations were performed using bioreactors inoculated with stools from healthy individuals ( = 4) or IBS-D patients ( = 4), when the M-ARCOL was set-up under healthy or IBS-D conditions. Setting IBS-D parameters in M-ARCOL inoculated with IBS-D stools maintained the key microbial features associated to the disease , validating the new system. In particular, compared to the healthy control, the IBS-D model was characterized by a decreased bacterial diversity, together with a lower abundance of and , but a higher level of and . Of interest, applying IBS-D parameters to healthy stools was not sufficient to trigger IBS-D dysbiosis and applying healthy parameters to IBS-D stools was not enough to restore microbial balance. This validated IBS-D colonic model can be used as a robust platform for studies focusing on gut microbes in the absence of the host, as well as for testing food and microbiota-related interventions aimed at personalized restoration of gut microbiota eubiosis.

摘要

肠易激综合征(IBS)是一种常见的慢性胃肠疾病,其中腹泻型肠易激综合征(IBS-D)是最常见的亚型。肠道微生物群在该疾病病因中的作用尚未完全明确。肠道系统可为临床前研究中的检测提供很好的替代方法,但尚未开发出能重现与IBS相关的微生物群落失调的模型。通过大量文献综述,建立了一种适应IBS-D理化和营养条件的新型黏膜人工结肠(M-ARCOL)。为了验证该模型并在机制研究中进一步挖掘其潜力,当M-ARCOL在健康或IBS-D条件下建立时,使用接种了健康个体(n = 4)或IBS-D患者(n = 4)粪便的生物反应器进行发酵。在接种IBS-D粪便的M-ARCOL中设置IBS-D参数可维持与该疾病相关的关键微生物特征,从而验证了这个新系统。特别是,与健康对照相比,IBS-D模型的特点是细菌多样性降低,同时[具体细菌名称1]和[具体细菌名称2]的丰度较低,但[具体细菌名称3]和[具体细菌名称4]的水平较高。有趣的是,将IBS-D参数应用于健康粪便不足以引发IBS-D微生物群落失调,而将健康参数应用于IBS-D粪便也不足以恢复微生物平衡。这个经过验证的IBS-D结肠模型可作为一个强大的平台,用于在无宿主的情况下专注于肠道微生物的研究,以及用于测试旨在个性化恢复肠道微生物群正常状态的食品和与微生物群相关的干预措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56b3/11796540/f67de7182cbd/KBIE_A_2458362_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56b3/11796540/d95d9363b165/KBIE_A_2458362_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56b3/11796540/8b2d319116f8/KBIE_A_2458362_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56b3/11796540/c934f4aa7a9a/KBIE_A_2458362_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56b3/11796540/51d900a58e7e/KBIE_A_2458362_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56b3/11796540/7f9b998d6dc4/KBIE_A_2458362_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56b3/11796540/f67de7182cbd/KBIE_A_2458362_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56b3/11796540/d95d9363b165/KBIE_A_2458362_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56b3/11796540/8b2d319116f8/KBIE_A_2458362_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56b3/11796540/c934f4aa7a9a/KBIE_A_2458362_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56b3/11796540/51d900a58e7e/KBIE_A_2458362_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56b3/11796540/7f9b998d6dc4/KBIE_A_2458362_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56b3/11796540/f67de7182cbd/KBIE_A_2458362_F0006_OC.jpg

相似文献

1
Gut microbial dysbiosis associated to diarrheic irritable bowel syndrome can be efficiently simulated in the Mucosal ARtificial COLon (M-ARCOL).与腹泻型肠易激综合征相关的肠道微生物失调可以在黏膜人工结肠(M-ARCOL)中得到有效模拟。
Bioengineered. 2025 Dec;16(1):2458362. doi: 10.1080/21655979.2025.2458362. Epub 2025 Feb 4.
2
Physical activity for treatment of irritable bowel syndrome.体力活动治疗肠易激综合征。
Cochrane Database Syst Rev. 2022 Jun 29;6(6):CD011497. doi: 10.1002/14651858.CD011497.pub2.
3
Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.替加色罗用于治疗肠易激综合征和慢性便秘。
Cochrane Database Syst Rev. 2007 Oct 17(4):CD003960. doi: 10.1002/14651858.CD003960.pub3.
4
Tegaserod for the treatment of irritable bowel syndrome.替加色罗用于治疗肠易激综合征。
Cochrane Database Syst Rev. 2004(1):CD003960. doi: 10.1002/14651858.CD003960.pub2.
5
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
6
Alterations of gut microbiota in patients with irritable bowel syndrome: A systematic review and meta-analysis.肠易激综合征患者肠道微生物群的改变:一项系统评价和荟萃分析。
J Gastroenterol Hepatol. 2017 Jan;32(1):28-38. doi: 10.1111/jgh.13471.
7
Dietary interventions for recurrent abdominal pain in childhood.儿童复发性腹痛的饮食干预措施
Cochrane Database Syst Rev. 2017 Mar 23;3(3):CD010972. doi: 10.1002/14651858.CD010972.pub2.
8
Synbiotics, prebiotics and probiotics for people with chronic kidney disease.慢性肾脏病患者的合生菌、益生元和益生菌。
Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD013631. doi: 10.1002/14651858.CD013631.pub2.
9
Synbiotics, prebiotics and probiotics for solid organ transplant recipients.固体器官移植受者的共生元、益生元和益生菌。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD014804. doi: 10.1002/14651858.CD014804.pub2.
10
Interleukin-6 in irritable bowel syndrome: A systematic review and meta-analysis of IL-6 (-G174C) and circulating IL-6 levels.肠易激综合征中的白细胞介素 6:白细胞介素 6(-G174C)和循环白细胞介素 6 水平的系统评价和荟萃分析。
Cytokine. 2017 Nov;99:132-138. doi: 10.1016/j.cyto.2017.08.017. Epub 2017 Sep 5.

本文引用的文献

1
Canine Mucosal Artificial Colon: development of a new colonic in vitro model adapted to dog sizes.犬类黏膜人工结肠:一种适应犬体型的新型结肠体外模型的开发。
Appl Microbiol Biotechnol. 2024 Jan 23;108(1):166. doi: 10.1007/s00253-023-12987-2.
2
Gut Dysbiosis in Irritable Bowel Syndrome: A Narrative Review on Correlation with Disease Subtypes and Novel Therapeutic Implications.肠易激综合征中的肠道菌群失调:关于与疾病亚型的相关性及新治疗意义的叙述性综述
Microorganisms. 2023 Sep 22;11(10):2369. doi: 10.3390/microorganisms11102369.
3
Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.
不同益生菌菌株和混合物在肠易激综合征中的疗效特异性:系统评价和网络荟萃分析。
Nutrients. 2023 Sep 4;15(17):3856. doi: 10.3390/nu15173856.
4
Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment.肠易激综合征:流行病学、重叠障碍、病理生理学和治疗。
World J Gastroenterol. 2023 Jul 14;29(26):4120-4135. doi: 10.3748/wjg.v29.i26.4120.
5
Colonic mucosal biopsy location can not affect the results of mucosal metabolomics and mucosal microbiota analysis in IBS.在肠易激综合征中,结肠黏膜活检部位不会影响黏膜代谢组学和黏膜微生物群分析的结果。
Front Med (Lausanne). 2023 Jun 7;10:1183484. doi: 10.3389/fmed.2023.1183484. eCollection 2023.
6
Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review.肠道微生物代谢物丁酸盐及其在炎症性肠病中的治疗作用:文献综述。
Nutrients. 2023 May 11;15(10):2275. doi: 10.3390/nu15102275.
7
Modelling of Oral Microbial Invasion in the Human Colon.人类结肠中口腔微生物入侵的模型构建
Microbiol Spectr. 2023 Mar 27;11(2):e0434422. doi: 10.1128/spectrum.04344-22.
8
Oral and fecal microbiota in patients with diarrheal irritable bowel syndrome.腹泻型肠易激综合征患者的口腔和粪便微生物群
Heliyon. 2023 Jan 20;9(1):e13114. doi: 10.1016/j.heliyon.2023.e13114. eCollection 2023 Jan.
9
Gut microbiome signatures reflect different subtypes of irritable bowel syndrome.肠道微生物群特征反映了不同亚型的肠易激综合征。
Gut Microbes. 2023 Jan-Dec;15(1):2157697. doi: 10.1080/19490976.2022.2157697.
10
Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial.腹泻型肠易激综合征患者中益生菌治疗应答者与非应答者肠道微生物群的组成变化:一项随机临床试验的事后分析
J Neurogastroenterol Motil. 2022 Oct 30;28(4):642-654. doi: 10.5056/jnm21202.